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The concepts of behavioral economics have proven to be useful for understanding the environmental
control of overall levels of responding for a variety of commodities, including reinforcement by drug
self-administration. These general concepts have implications for the assessment of abuse liability
and drug abuse intervention and the formulation of public policy on drug abuse. An essential
requirement is the ability to compare the demand for different drugs directly in order to assess
relative abuse liability, and to compare demand for the same drug under different environmental
and biological interventions to assess their ability to reduce demand. Until now, such comparisons
were hampered by the confounding effect of varying drug doses and potencies that prevent quan-
titative comparisons of demand elasticity-sensitivity of consumption and responding to the con-
straint of price (effort). In this paper we describe a procedure to normalize demand-curve analysis
that permits dose- and potency-independent comparisons of demand across drugs. The procedure
is shown to be effective for comparing drug demand within and across the drug classes. The tech-
nique permits a quantitative ordering of demand that is consistent with the peak levels of responding
maintained by the drugs. The same technique is generalized for the comparison of other types of
reinforcers under different biological conditions.
Key words: behavioral economics, normalized demand, demand curve, elasticity, drug self-admin-
istration, cost, unit price, fixed-ratio schedule, overall response output, cocaine, alfentanil, nalbu-
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Among the many advantages of behavioral
economics is its ability to focus our attention
on those environmental and biological vari-
ables that control an organism's level of per-
formance to obtain specific reinforcers, apart
from local patterns of performance or peri-
odicities in consumption. This makes behav-
ioral economics an ideal framework for ana-
lyzing behavior that occurs at such high levels
in relation to the benefit it confers that it is
considered to be "abusive"; an example is
substance abuse (Brady & Lukas, 1984; Grif-
fiths, Bigelow, & Henningfield, 1980; Johan-
son, 1978).
Behavioral economics has been shown to
be a valuable tool for analyzing drug self-ad-
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ministration in animal models of drug abuse.
Studies have applied economic concepts to
the assessment of the level of consumption
and its sensitivity to increases in effort to ob-
tain the drug (Bickel, DeGrandpre, Higgins,
& Hughes, 1990; Bickel, DeGrandpre,
Hughes, & Higgins, 1991; Carroll, Carmona,
& May, 1991; Winger, 1993b). Other studies
have used these concepts to evaluate the ef-
fects of various variables that might alter
maintenance of drug self-administration
(Carroll et al., 1991; Comer, Hunt, & Carroll,
1994).
In several previous studies, Hursh (1991,
1993) has proposed that behavioral econom-
ics can be applied in four general domains
for the analysis of drug abuse: (a) abuse lia-
bility, the assessment of a drug's potential to
serve as a reinforcer and the strength of that
reinforcer function in comparison with other
drugs; (b) drug interactions, the capacity for
consumption of one drug to either interfere
with or enhance the level of performance to
obtain another drug; (c) drug abuse interven-
tions, the capacity for some change in the
context of drug self-administration, including
the administration of medications, to alter
performance to obtain a drug; and (d) public
policy formulation, the potential effects of pub-
lic policy on the general demand for drugs,
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Fig. 1. Representative demand curve (left panel) and response output function (right panel) for phencyclidine
(PCP) by monkeys (data from Carroll, 1987). Total daily consumption of drug and total response output are plotted
as a function of unit price (responses per mg/ml/reinforcer) with logarithmic scales.
financial expenditures for drugs by the com-
munity, revenue potential for drug suppliers,
and incentives to engage in criminal behavior
to buy or sell drugs. As described previously
(Hursh, 1991, 1993), all of these applications
hinge on an analysis of demand for drugs and
variables that alter demand, particularly elas-
ticity of demand, which is the sensitivity of
consumption to changes in price for a unit
of drug reinforcement. In this article we de-
scribe an advance in the mathematical treat-
ment of demand for drugs that will permit
comparisons of elasticity of demand across
drug doses and potencies, thereby advancing
all four domains of drug abuse analysis using
behavioral economics. In addition, we gen-
eralize this approach to the analysis and com-
parison of demand for any group of reinforc-
ers.
Demand-Curve Analysis
The fundamental metric for an economic
analysis of drug self-administration is the de-
mand curve (Hursh, 1980, 1984; Hursh &
Bauman, 1987; Lea, 1978; Raslear, Bauman,
Hursh, Shurtdeff, & Simmons, 1988). The de-
mand curve describes the relationship be-
tween total consumption of a commodity and
its price, expressed as effort per unit of re-
inforcement. Figure 1 displays a representa-
tive demand curve for phencyclidine (PCP)
by rhesus monkeys. Two oral doses of drug
(0.125 mg/ml and 0.25 mg/ml) were deliv-
ered under increasing fixed-ratio (FR) sched-
ules (data from Carroll et al., 1991). The de-
mand curve has two basic features-its initial
level at the lowest price and its negative slope
with increases in price. When plotted in log-
log coordinates, the slope reflects propor-
tional changes in consumption relative to
proportional changes in price and is called
elasticity of demand. If proportional changes
in consumption are small in relation to pro-
portional changes in price (the curve has a
slope less negative than -1), then demand is
said to be inelastic (Watson & Holman,
1977). In order to demonstrate inelastic de-
mand, the subject must increase the total
amount of responding with each increase in
price (see Figure 1, right panel).
If proportional changes in consumption
are large relative to proportional changes in
price (the curve has a slope more negative
than -1), then demand is said to be elastic
and the corresponding response output func-
tion decreases with each increase in price.
Most demand curves are nonlinear (as in Fig-
ure 1, left panel) and are inelastic across a
range of low prices and elastic at higher pric-
es. The accompanying response output func-
tion is an inverted U-shaped function (Figure
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Fig. 2. Unit-price demand curves for cocaine and methohexital (bottom panel) (Winger, 1993a) and for alfentanil
and nalbuphine (top panel) (Winger et al., in press). In each, total daily consumption of drug is plotted as a function
of unit price (responses per mg/kg/reinforcer) with logarithmic scales.
(adjusted for body weight, e.g., mg/kg) per
day, and unit price is number of responses
per reinforcer divided by total weight of drug
per reinforcer. For a variety of drug reinforc-
ers, different doses yielded similar demand
curves when plotted in these terms (Bickel et
al., 1990). In other words, by accounting for
differences in magnitude of reinforcement
using unit price and total drug consumption,
there were little or no residual elasticity dif-
ferences between demand curves for the
same drug given at different doses.
Demand curves defined in terms of unit
price have two potential shortcomings. First,
they cannot compensate for the other com-
ponent of drug reinforcer magnitude, its po-
tency. For example, when comparing de-
mand for two opioid agonists nalbuphine and
alfentanil, Winger, Woods, and Hursh (in
press) showed that nearly 10 times as much
nalbuphine was consumed at the lowest unit
price as alfentanil, but the nalbuphine ceased
to support responding at much lower unit
prices compared to alfentanil (see Figure 2).
As pointed out by Hursh et al. (1988), this
pattern of results might be expected if nal-
buphine has a lower reinforcer magnitude





















tanil, a conclusion that is supported by evi-
dence that nalbuphine has lower potency and
efficacy than alfentanil when their thermal
analgesic affects were compared (Walker, Bu-
telman, DeCosta, & Woods, 1993). A differ-
ence in magnitude does not necessarily indi-
cate a basic difference in elasticity. As
discussed above, one food pellet has lower re-
inforcer magnitude than two food pellets, but
demand curves adjusted for this difference in
size have identical elasticity of demand
(Hursh et al., 1988). However, until now, no
method existed to estimate potency differ-
ences among drugs to similarly adjust their
demand curves so that they can be compared
without the confounding effect of quantita-
tive differences in magnitude.
The second shortcoming of unit price is
that it makes the strong assumptions that the
relationship between dose and magnitude is
linear (i.e., that a doubling of dose yields a
doubling of reinforcer magnitude). Although
this may be true within a range of effective
reinforcing doses for most drugs, it is appar-
ently not true for cocaine. Winger (1993b)
showed that a unit price conversion of de-
mand for cocaine did not result in a clear
convergence to a single function; rather,
three demand curves were evident, especially
for the lowest dose compared to the higher
two doses (see Figure 2, explained below).
The method for computing demand curves
described below corrects for any differences
in reinforcer magnitude. With drug reinforc-
ers, this includes differences in the arranged
dose per reinforcer and differences in poten-
cy. The method is essentially a normalization
procedure. The average daily consumption
observed with the smallest FR at each dose is
taken as a reference level of consumption for
that dose of the drug. This level is "defend-
ed" under the challenge of increasing prices
or effort per reinforcer. The normalization
procedure defines the demand curve in
terms of percentage decreases from this ref-
erence level with increases in price. Elasticity
of demand is the slope of this function in log-
log coordinates and reflects the degree to
which the subject emits increasing numbers
of responses under increasing effort or re-
sponse requirements (e.g., FR schedules) to
prevent decreases from the average daily level
of consumption at the lowest FR.
In order to carry out this normalization
procedure, each drug dose is converted to a
normalized unit that is this dose expressed as
a percentage of the average total daily drug
consumption of that dose at the lowest FR.
For a drug with an average daily consumption
of 100 mg/kg per day at the lowest FR, a dose
of 1 mg/kg per reinforcer would be a nor-
malized dose, q, of 1.0, expressed as a per-
centage computed as follows:
d
q= () x 100,q(dB)
where q is the normalized dose, d is the dose
per reinforcer (e.g., injection), and B is the
average of reinforcers per day of that dose at
the lowest FR. Because dose per reinforcer, d,
cancels, we find that normalized dose is sim-
ply q = 100 . B. Normalized consumption
and price under each FR schedule are com-
puted in terms of the q value for each dose:
P = FR . q, and Q = Rq. (FR is the fixed-
ratio value, R is the number of reinforcers per
day at an FR value, P is the normalized price,
and Q is the normalized consumption.) Be-
cause q is in percentage units, dose and po-
tency are no longer factors in determining
the demand function. Also note that at the
lowest FR value, Q will always equal 100;
hence, all normalized demand curves have a
starting level of 100.
Comparisons of Different Doses and Drugs
Data from two previous studies (Winger,
1993a; Winger et al., in press) were used to
test the validity of the method. In the first
study (Winger, 1993a), consumption of two
drugs (cocaine and methohexital) was com-
pared across a range of doses and FR sched-
ules (FRs of 10, 17, 32, 56, 100, 178, 320, 560,
and 1,000). In the second study (Winger et
al., in press), two opioid agonists (alfentanil
and nalbuphine) were compared across doses
and a similar range of FR schedules. The sub-
jects were adult rhesus monkeys (7 in Winger,
1993a; 11 in Winger et al., in press). Drug was
dispensed through indwelling intravenous
catheters. The primary data used for this
comparison were the average number of in-
jections per day of each drug and dose across
subjects (shown in Table 1). For comparison
to the more conventional method of plotting
demand curves, Figure 2 displays daily con-
sumption (dose per injection X injections
per day) of each drug as a function of unit
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Table 1
Mean number of injections per day under each FR schedule and normalized dose (q) for
each drug.
Fixed Alfentanil (mg/kg) Nalbuphine (mg/kg) Cocaine (mg/kg) Methohexital (mg/kg)
ratio 0.01 0.003 0.001 0.0003 0.32 0.03 0.01 0.00 0.10 0.03 0.01 1.00 0.32 0.10
10 31.0 70.0 151.0 209.0 13.60 31.00 43.10 66.30 69.10 144.13 141.90 23.00 59.00 132.00
18 27.0 63.0 142.0 226.0 9.80 27.50 26.50 45.50 63.80 117.90 153.80 21.00 50.00 115.00
32 24.0 61.0 105.0 163.0 9.30 22.00 33.00 39.20 53.70 85.40 53.30 0.21 47.00 84.00
56 24.0 47.0 91.0 123.0 6.50 17.00 24.90 30.40 44.17 74.00 30.30 21.00 43.00 40.00
100 20.0 40.0 62.0 79.0 4.30 16.00 19.00 20.80 32.17 58.40 13.30 18.00 31.00 23.00
178 20.0 29.0 38.5 40.0 4.00 7.70 11.20 15.80 30.10 31.00 6.10 16.00 22.00 11.00
320 15.0 18.0 20.7 20.0 3.90 5.10 9.20 6.20 22.75 11.70 2.75 10.00 10.00 4.00
560 11.0 10.5 11.2 10.0 3.00 2.20 4.00 1.80 16.50 8.50 9.00 2.00
1,000 7.0 6.3 3.4 4.0 1.16 1.60 2.20 0.75 8.35 0.00
q 3.22 1.43 0.66 0.48 7.35 3.23 2.32 1.51 1.45 0.69 0.70 4.35 1.69 0.76
price computed as responses per milligram
per kilogram. Fitted demand functions were
computed using Equation 1. For cocaine and
methohexital (bottom two panels of Figure
2), much higher levels of methohexital were
consumed compared to cocaine, but con-
sumption of methohexital ceased at much
lower unit prices (note the logarithmic
scales). Because the functions are nonlinear
and start at different levels, it is impossible to
determine which drug supports the more in-
elastic demand. Similarly, for the two opioids
(top two panels of Figure 2), nalbuphine was
consumed in much larger quantities than al-
fentanil but ceased to support responding at
lower prices. Within each drug, the compu-
tation of unit price yields a single demand
curve, except for cocaine, which appears to
support higher levels of demand at higher
doses (the function was fitted to the higher
two doses only).
Normalization for dose. Figure 3 displays
these same results in terms of normalized de-
mand curves. The normalized curves all start
at a baseline level of 100%. The curves de-
cline at different rates that reflect different
rates of change in consumption relative to
consumption at the lowest FR as a function
of increasing normalized price.
The function fitted to the data was a sim-
plified version of Equation 1. Because nor-
malization resulted in an adjustment of the
initial level of consumption to 100%, the level
parameter, L, in Equation 1 was replaced with
the constant 100:
ln(0 = ln(100) + b[ln(P)] - a(P). (3)
Although Equation 3 is a two-parameter func-
tion, the overall model continues to have
three parameters because normalized dose, q,
used to transform price and quantity con-
sumed, is an empirically derived parameter
based on the average number of injections
under each drug dose at the lowest FR. The
equation was fitted to the pooled data for
each drug across all doses, except the lowest
dose of cocaine. The values for normalized
dose, q, used for the analysis are shown in
Table 1. The results of the regression analysis
are shown in Table 2. This normalized ver-
sion of the demand equation accounted for
92% to 96% of the variance in the data shown
in Figure 3. The average R2 was .935, slightly
better than that found with the analysis of
unit price shown in Figure 2 (mean R2 of
.933). The fit to various doses of alfentanil
was superior with normalization compared to
unit price, with R2 of .94 and .89, respectively;
fits were approximately equal for the two
techniques with methohexital and nalbu-
phine, and the fit was worse for cocaine with
normalization compared to unit price, with
R2 of .92 and .95, respectively. The point of
maximal output (elasticity of -1), Pm., was
computed using Equation 2 and is shown in
Table 2 and Figure 3 as a vertical dotted line.
It can be seen that Pm.. is higher for alfentanil
and cocaine than for nalbuphine and me-
thohexital. This indicates greater inelasticity
of demand for alfentanil and cocaine in this
behavioral procedure.
The normalization procedure was success-
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Fig. 3. Normalized demand curves for the drugs analysis, nalbuphine, cocaine, and methohexital (Winger, 1993a;
Winger et al., in press) by monkeys. Normalized consumption is plotted as a function of normalized price with
logarithmic scales (see text for explanation). The dotted line represents the point of peak responding, P...
Table 2
Results of regression analysis of data in Table 1 and Figure 3 using Equation 3 applied to
normlized prices and consumptions pooled across doses of each drug. Values of q used for
normalization are shown in Table 1. Shown are parameter estimates, R2, and P;,.. values for
each drug.
Parameter Alfentanil Nalbuphine Cocaine Methohexital
a 0.00184 0.00486 0.00273 0.00883
b -0.1071 -0.2287 -0.09729 -0.02946
R2 0.94 0.92 0.92 0.96
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Fig. 4. Fitted functions to the normalized demand curves in Figure 3. Values of Pma, for each drug are shown as
one metric for ordering level of demand. See text for explanation.
that the data for a single drug converge to a
single function, except for the lowest dose of
cocaine; this appears to support a much more
elastic and linear demand curve, not unlike
the results with the analysis of unit price in
Figure 2. This persistent difference between
demand for the lowest dose of cocaine and
higher doses supports one of two conclu-
sions: (a) that normalization is no better than
unit price in correcting for nonlinearities be-
tween dose and magnitude, or (b) that the
lowest dose of cocaine differs qualitatively
from higher doses and represents more than
a quantitative magnitude shift.
It is difficult to discriminate firmly between
these two conclusions; however, normaliza-
tion certainly uses the subjects' own evalua-
tion of the drug in terms of total consump-
tion to correct for dose differences. One
would expect that this would reduce, if not
eliminate, any nonlinearities between dose
and magnitude. The fact that the difference
between the lowest dose and higher doses ap-
pears to be unchanged under these condi-
tions seems to support the second conclusion
that more than a magnitude shift is involved.
One interpretation is that the lowest dose of
cocaine is only a marginally effective primary
reinforcer and derives its strength as a rein-
forcer from some form of conditioned rein-
forcement due to sensory similarities to the
effects of higher doses. It might not be sur-
prising that a conditioned reinforcer sup-
ports qualitatively different demand com-
pared to primary reinforcers. See Bickel,
DeGrandpre, and Higgins (1993) for further
discussion of this issue.
Normalization for potency. The correction for
potency can be seen most clearly in Figure 4,
in which the fitted functions were plotted to-
gether for comparison. The demand curves









and showed the least elasticity of the group.
Methohexital showed a small initial slope that
rapidly increased such that it showed the low-
est consumption at the highest normalized
prices. Nalbuphine had the greatest initial
slope (b in Equation 3) but an acceleration
parameter (a in Equation 3) about half that
of methohexital.
A convenient way to compare elasticity
across demand curves that have continuously
varying slopes and elasticities is in terms of
the point on the price dimension at which
they each reach a slope of -1.0. This hap-
pens to be the point at which responding
reaches its peak, the defined boundary be-
tween inelastic and elastic demand. The
greater the general elasticity of a demand
curve, the lower the price that generates peak
response output. This point is the price with
maximum output, Pmax, and is shown in Table
2 and Figure 4. Alfentanil showed peak re-
sponding at the highest price of 486, followed
by cocaine at 331. Nalbuphine and metho-
hexital had PmaxC values less than half those of
the other two drugs (159 and 110, respective-
ly). Assessment of demand based on compar-
ison of elasticities indicated by Pm., values
gives an ordering as follows: alfentanil > co-
caine > nalbuphine > methohexital.
One drawback of comparing demand en-
tirely in terms of differences in elasticity is
that it ignores differences in level of con-
sumption that could significantly affect the
total amount of performance emitted per day
to obtain the reinforcer. Another approach to
assessing demand that considers both elastic-
ity and level of demand is in terms of area
under the normalized demand curve. By in-
spection, this leads to a slightly different or-
dering as follows: alfentanil cocaine >
methohexital > nalbuphine. The area meth-
od gives an ordering consistent with the peak
amounts of responding maintained by each
drug. This is not surprising. If one draws a
rectangle under each curve bounded on the
x axis by Pma,, and bounded on the y axis by
the level of demand at Pm. the area of that
rectangle in arithmetic units is mathematical-
ly equal to the peak amount of responding,
as illustrated in Figure 5.
If F&a is the FR value at Pmax, Rma, is the
number of reinforcers at Pm., and 0max is the
peak response output at P.,., then
area = FRm,, X qRm".
q
The q values cancel, reducing to: area =
(FRmg) X (Rm.) = Omax Because the units of
FR are responses per reinforcer and the units
of consumption (R) are reinforcers, the re-
inforcer units cancel, giving the response lev-
el at Pmx, which is Omax or maximum output
of responding. Maximum output is sensitive
both to changes in elasticity that alter Pma.
and to changes in the level of consumption,
reflected in Rmr. Also, the calculation of this
area and 0m. does not include a term for q,
the normalized dose. This means that the
area defined by Pmax under the demand curve
and its mathematical equivalent, max, peak
response output, are dose- and potency-in-
dependent metrics for comparing demand.
These features of Omax make it a sensitive tool
for direct comparison and quantitative order-
ing of demand, both within and across the
drug classes (stimulant, sedative, and opioid)
represented by these four drugs.
The procedure reported here for comput-
ing normalized price is mathematically simi-
lar to an earlier proposal by Timberlake and
Peden (1987). They transformed each re-
sponse requirement to reward density, which
was mathematically equivalent to q/FN, the
inverse of normalized price as presented
here. They proposed that all response-rate
functions should converge to a single curve
when plotted as a function of reward density.
By implication, this predicts that all normal-
ized demand curves should overlap and have
equal Pmx.. The results shown in Figures 3
and 4 confirm this prediction for different
doses of a single drug but contradict the pre-
diction across different drugs.
Other Reinforcers
The method described here may be used
to compare elasticities of any reinforcers. For
example, in Hursh et al. (1988), demand for
food by normal monkeys was compared to de-
mand by monkeys with lesions of the ventro-
medial nuclei of the hypothalamus (VMH)
which produce hyperphagia and obesity (data
from Hamilton & Brobeck, 1964). Compared
to normal monkeys, obese VMH monkeys eat
much more food at low FRs and less food at
high FRs. This has led to a two-factor theory
of how this lesion alters food regulation. First,
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Fig. 5. Illustration of the relationship between area under the demand curve, as bounded by P,.. and the level
of demand at P,,,, and the total level of responding at P.., known as Oma.. This area under the demand curve is
an alternative metric for ordering level of demand and is consistent with the peak level of responding maintained
by the drug.
it increases the baseline set point for satiety.
Second, it reduces overall drive for food,
leading to greater sensitivity to constraints
such as FR schedules. Hamilton and Brobeck
tested monkeys under a series of FR sched-
ules that ranged from FR 1 to FR 1,024 in a
closed economy (Hursh, 1980, 1984). Obese
subjects ate 2.7 times as much food as normal
subjects at FR 1 but consumed less food at FR
values greater than FR 64.
Hursh et al. (1988) proposed that a quan-
titative magnitude difference in the food as
processed by the two groups could account
for both aspects of consumption. To test this
hypothesis, we applied the normalization pro-
cedure to those data; the results are displayed
in Figure 6. Normalization treats consump-
tion at FR 1 as 100% for both groups. Each
food pellet represented a different propor-
tion of each group's normal intake. For the
normal group, each food pellet was 1.25% of
baseline consumption (q = 1.25). For the
obese subjects, each pellet was only 0.46% of
daily intake (q = 0.46). Thus, for obese ani-
mals, each pellet was worth only about 37%
as much as a pellet for a normal monkey. This
represents a quantitative magnitude differ-
ence that must be taken into account to com-
pare demand by the two groups fairly. In par-
ticular, equivalent FR values had functionally
larger cost-benefit ratios for the obese ani-
mals. This magnitude difference is compen-
sated for when the demand curves are plot-
ted in normalized units. Figure 6 shows that
when equal prices represent equivalent cost-
benefit ratios, the two demand curves show
equal sensitivity to price increases and con-
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Fig. 6. Normalized demand for food by normal and
obese monkeys with VMH lesions. Fitted demand curves
to the data from the two groups are nearly identical, in-
dicating similar elasticities of demand in the face of in-
creasing normalized prices (data from Hamilton & Bro-
beck, 1964).
normalized demand curves reveal nearly
identical elasticities across the range of pric-
es. Both normal and obese animals defended
their baseline levels of consumption to the
same degree in the face of equivalent increas-
es in the normalized price of food. One can
infer from this, then, that the lesion has only
one effect on food consumption: It alters the
set point for satiety represented by the differ-
ences in the maximum daily consumption at
the lowest FR. This, in turn, alters the func-
tional magnitude of each pellet in terms of
its contribution to satiety and, further, alters
the functional cost of each FR schedule.
Implications
If one can draw an analogy between this
lesion study and strategies to alter demand
for drugs biologically, the normalization pro-
cedure will permit researchers to determine
if such interventions merely alter baseline po-
tency, analogous to the level shift in food con-
sumption produced by VMH lesions, or truly
alter elasticity of demand, as seen in the dif-
ferences between, for example, demand for
cocaine and methohexital in Figure 4. In par-
ticular, it would be valuable to compare the
effectiveness of antagonists that reduce the
potency of the target drug to interventions
that provide substitute agonists, which, based
on the analysis in Hursh (1991), would be
expected to produce an increase in demand
elasticity for the target drug. The normalized
demand procedure described here would
permit a fair comparison of interventions in-
dependent of quantitative shifts in reinforcer
magnitude of the target drug. Only those in-
terventions that increase elasticity and reduce
either Pm. or the area under the demand
curve would be expected to reduce the peak
level of performance to obtain the drug and
remediate the adverse social consequences
that attend such excessive behavior.
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